Stifel Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $332

Stifel analyst Annabel Samimy maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $255 to $332.